Cardioprotective effect of ultrasound‐targeted destruction of Sirt3‐loaded cationic microbubbles in a large animal model of pathological cardiac hypertrophy

• Published in: Acta biomaterialia Vol. 164; pp. 604 - 625
• Main Authors: Qin, Xionghai, Cai, Peian, Liu, Chang, Chen, Kegong, Jiang, Xingpei, Chen, Wei, Li, Jiarou, Jiao, Xuan, Guo, Erliang, Yu, Yixiu, Sun, Lu, Tian, Hai
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01-07-2023
• Subjects: Animals; Cardiomegaly; Cationic microbubbles; Fibrosis; Gene delivery; Heart Failure; Humans; Lipids; Male; Microbubbles; Models, Animal; Pathological myocardial hypertrophy; Pig; Prospective Studies; Sirtuin 3; Sirtuin3; Swine; Ultrasound Targeted Microbubble Destruction; Sirtuin3; Bcl-2; DHE; FDA; CMBs; Ultrasound Targeted Microbubble Destruction; DC-CHOL; FS; UTMD; HSirt3; LV mass; C3F8; DPPC; PBS; AB; LVPWd; H&E; DSPE-PEG2000; Foxo3a; PSirt3; PSR; Pig; Gene delivery; Pathological myocardial hypertrophy; Bax; PI; Cationic microbubbles; IVSd; TEM; PCR; LVH
• ISSN: 1742-7061; 1878-7568
• DOI: 10.1016/j.actbio.2023.04.020

Pathological cardiac hypertrophy occurs in response to numerous increased afterload stimuli and precedes irreversible heart failure (HF). Therefore, therapies that ameliorate pathological cardiac hypertrophy are urgently required. Sirtuin 3 (Sirt3) is a main member of histone deacetylase class III and is a crucial anti-oxidative stress agent. Therapeutically enhancing the Sirt3 transfection efficiency in the heart would broaden the potential clinical application of Sirt3. Ultrasound-targeted microbubble destruction (UTMD) is a prospective, noninvasive, repeatable, and targeted gene delivery technique. In the present study, we explored the potential and safety of UTMD as a delivery tool for Sirt3 in hypertrophic heart tissues using adult male Bama miniature pigs. Pigs were subjected to ear vein delivery of human Sirt3 together with UTMD of cationic microbubbles (CMBs). Fluorescence imaging, western blotting, and quantitative real-time PCR revealed that the targeted destruction of ultrasonic CMBs in cardiac tissues greatly boosted Sirt3 delivery. Overexpression of Sirt3 ameliorated oxidative stress and partially improved the diastolic function and prevented the apoptosis and profibrotic response. Lastly, our data revealed that Sirt3 may regulate the potential transcription of catalase and MnSOD through Foxo3a. Combining the advantages of ultrasound CMBs with preclinical hypertrophy large animal models for gene delivery, we established a classical hypertrophy model as well as a strategy for the targeted delivery of genes to hypertrophic heart tissues. Since oxidative stress, fibrosis and apoptosis are indispensable in the evolution of cardiac hypertrophy and heart failure, our findings suggest that Sirt3 is a promising therapeutic option for these diseases.
Pathological cardiac hypertrophy is a central prepathology of heart failure and is seen to eventually precede it. Feasible targets that may prevent or reverse disease progression are scarce and urgently needed. In this study, we developed surface-filled lipid octafluoropropane gas core cationic microbubbles that could target the release of human Sirt3 reactivating the endogenous Sirt3 in hypertrophic hearts and protect against oxidative stress in a pig model of cardiac hypertrophy induced by aortic banding. Sirt3-CMBs may enhance cardiac diastolic function and ameliorate fibrosis and apoptosis. Our work provides a classical cationic lipid-based, UTMD-mediated Sirt3 delivery system for the treatment of Sirt3 in patients with established cardiac hypertrophy, as well as a promising therapeutic target to combat pathological cardiac hypertrophy.
[Display omitted]